You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 52 No. 10, October 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Use of Buspirone for Treatment of Cerebellar Ataxia

An Open-Label Study

Jau-Shin Lou, MD, PhD; Lev Goldfarb, MD, PhD; Lisa McShane, PhD; Plamen Gatev, MD, PhD; Mark Hallett, MD

Arch Neurol. 1995;52(10):982-988.


Abstract

Objective
To evaluate the efficacy of buspirone hydrochloride, a serotonin (5-hydroxytryptamine1A) agonist, in treating patients with cerebellar ataxia.

Design
Open-label study in which 20 patients (14 with cerebellar cortical atrophy and six with olivopontocerebellar atrophy) received buspirone hydrochloride, up to 60 mg/d, for 8 weeks.

Setting
Research hospital.

Main Outcome Measures
Clinical, physiological, and psychological assessment.

Results
Nine patients with mild or moderate cerebellar dysfunction who completed the study showed significant improvement in clinical and self-assessment ratings, but not in a motor performance test, posturography (data were incomplete), State-Trait Anxiety Inventory, and Beck Depression Inventory. Seven patients with severe cerebellar dysfunction who completed the study had no improvement on any measure.

Conclusions
Buspirone may be effective in treating mild to moderate cerebellar ataxia. A double-blind study of the efficacy of buspirone in cerebellar ataxia is warranted.



Author Affiliations

From the Human Motor Control Section, Medical Neurology Branch (Drs Lou, Goldfarb, Gatev, and Hallett), and the Biometry and Field Studies Branch (Dr McShane), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale
Subramony et al.
Neurology 2005;64:1261-1262.
ABSTRACT | FULL TEXT  

Inhibitory Presynaptic 5-Hydroxytryptamine2A Receptors Regulate Evoked Glutamate Release from Rat Cerebellar Mossy Fibers
Marcoli et al.
J. Pharmacol. Exp. Ther. 2001;299:1106-1111.
ABSTRACT | FULL TEXT  

Trazodone is a Potent Agonist at 5-HT2C Receptors Mediating Inhibition of the N-Methyl-D-Aspartate/Nitric Oxide/Cyclic GMP Pathway in Rat Cerebellum
Marcoli et al.
J. Pharmacol. Exp. Ther. 1998;285:983-986.
ABSTRACT | FULL TEXT  

Some Reminders That Serotonin Also Affects Neurologic Conditions
JWatch Psychiatry 1995;1995:11-11.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.